$13.33
0.295[2.26%]
At close: Apr 19
$13.33
0[0.00%]
After Hours: 4:20PM EDT
Sage Therapeutics
(NASDAQ:SAGE)Sage Therapeutics Stock (NASDAQ:SAGE), Analyst Ratings, Price Targets, Predictions
Sage Therapeutics Inc has a consensus price target of $29.76, established from looking at the 94 latest analyst ratings. The last 3 analyst ratings were released from Scotiabank, Oppenheimer, and TD Cowen on April 18, 2024. With an average price target of $17.33 between Scotiabank, Oppenheimer, and TD Cowen, there's an implied 30.03% upside for Sage Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
Oppenheimer
TD Cowen
Needham
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sage Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 42.54% | Scotiabank | George Farmer | $34 → $19 | Maintains | Sector Outperform | Get Alert |
| 04/18/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 27.53% | Oppenheimer | Jay Olson | $25 → $17 | Maintains | Perform | Get Alert |
| 04/18/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 20.03% | TD Cowen | Ritu Baral | $30 → $16 | Maintains | Buy | Get Alert |
| 04/18/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 110.05% | HC Wainwright & Co. | Douglas Tsao | → $28 | Reiterates | Neutral → Neutral | Get Alert |
| 04/17/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 80.05% | Wedbush | Laura Chico | → $24 | Reiterates | Neutral → Neutral | Get Alert |
| 04/17/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 5.03% | B of A Securities | Tazeen Ahmad | $24 → $14 | Downgrade | Neutral → Underperform | Get Alert |
| 03/26/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 117.55% | JP Morgan | Anupam Rama | $24 → $29 | Maintains | Overweight | Get Alert |
| 03/11/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 95.05% | RBC Capital | Brian Abrahams | → $26 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 02/28/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 65.04% | Morgan Stanley | Vikram Purohit | $20 → $22 | Maintains | Equal-Weight | Get Alert |
| 02/15/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 110.05% | HC Wainwright & Co. | Douglas Tsao | $25 → $28 | Maintains | Neutral | Get Alert |
| 02/15/2024 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 95.05% | RBC Capital | Brian Abrahams | $21 → $26 | Maintains | Sector Perform | Get Alert |
| 12/18/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 50.04% | Stifel | Paul Matteis | $22 → $20 | Maintains | Hold | Get Alert |
| 12/12/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 57.54% | Deutsche Bank | Neena Bitritto-Garg | → $21 | Initiates | → Hold | Get Alert |
| 11/08/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 57.54% | RBC Capital | Brian Abrahams | $22 → $21 | Maintains | Sector Perform | Get Alert |
| 11/08/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 65.04% | Wedbush | Laura Chico | $21 → $22 | Maintains | Neutral | Get Alert |
| 10/13/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 87.55% | Goldman Sachs | Salveen Richter | $22 → $25 | Maintains | Neutral | Get Alert |
| 09/08/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 80.05% | B of A Securities | Tazeen Ahmad | $25 → $24 | Maintains | Neutral | Get Alert |
| 09/07/2023 | SAGE | Buy Now | Sage Therapeutics | $13.33 | 50.04% | Mizuho | Vamil Divan | $19 → $20 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Sage Therapeutics (SAGE)?
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by Scotiabank on April 18, 2024. The analyst firm set a price target for $19.00 expecting SAGE to rise to within 12 months (a possible 42.54% upside). 48 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sage Therapeutics (SAGE)?
The latest analyst rating for Sage Therapeutics (NASDAQ: SAGE) was provided by Scotiabank, and Sage Therapeutics maintained their sector outperform rating.
When was the last upgrade for Sage Therapeutics (SAGE)?
The last upgrade for Sage Therapeutics Inc happened on March 13, 2023 when RBC Capital raised their price target to $60. RBC Capital previously had a sector perform for Sage Therapeutics Inc.
When was the last downgrade for Sage Therapeutics (SAGE)?
The last downgrade for Sage Therapeutics Inc happened on April 17, 2024 when B of A Securities changed their price target from $24 to $14 for Sage Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sage Therapeutics (SAGE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sage Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sage Therapeutics was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Sage Therapeutics (SAGE) correct?
While ratings are subjective and will change, the latest Sage Therapeutics (SAGE) rating was a maintained with a price target of $34.00 to $19.00. The current price Sage Therapeutics (SAGE) is trading at is $13.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.